Most of what determines a GLP-1 bill in the United States is decided before anyone reads a price page. Whether a plan covers the drug at all, what copay it sets, and whether the prescription is written for obesity or for diabetes each move the number by more than any seller’s discount does. The cash market this site prices exists because so many of those answers are no, which is what the price check sets a quote against.
The exclusion is written into the statute
Medicare Part D was constructed with drugs for weight loss explicitly excluded, on the reasoning available when the benefit was designed: the agents of the day had limited effectiveness and were perceived as cosmetic[1]. That exclusion is a matter of law rather than of current evidence, and unwinding it needs either legislation or a demonstration waiver rather than a clinical argument[1].
State Medicaid programs are not bound by the same exclusion and have moved in different directions, which is why coverage for the same drug differs across a state line. A study of state Medicaid coverage and reimbursement examined those policies and their trends from 2011 to 2022[2]. Commercial coverage has its own patchwork; a policy review of the landscape describes access as severely limited despite the efficacy of the newer agents, and draws the parallel with how coverage for bariatric surgery was eventually expanded[3].
What a copay does to whether anyone finishes
The clearest published link between price and behavior comes from a cohort of 15,811 commercially insured US adults who started semaglutide for weight management between June 2021 and December 2023[4]. By the fifth month, 46% had discontinued treatment, and the rate was essentially unchanged at 48% among those who started after the supply shortage resolved[4].
Discontinuation was strongly associated with the amount a patient paid. It rose from 41% in the lowest copayment quintile, $1 to $54 a month, to 51% in the highest, $161 to $1,460 a month[4]. Lower household income and lower education level were associated with higher discontinuation as well[4]. Most people in that cohort also deviated from the recommended dose-escalation schedule inside the first five months.
Coverage changes what gets prescribed, not just what gets paid
A retrospective pre-post study at a large tertiary center analyzed 2,060 patients seen in January and April 2024, bracketing a state Medicaid coverage change for anti-obesity medications[5]. Patients with private insurance were more likely to be prescribed semaglutide or tirzepatide, with an adjusted odds ratio of 2.744 (p < 0.001)[5].
In the January window, Black and Hispanic patients were 49% and 47% less likely to be prescribed those drugs (p = 0.003 and p = 0.025). In the April window, after the coverage change, that difference was no longer apparent[5]. A single state’s policy decision moved who received a prescription at all, which is a larger effect than any discount on this site’s roster.
What this means for a cash price
The cash market is what remains after those decisions. A seller advertising a monthly figure is competing against a coverage answer the buyer has usually already received, and the practical question is not whether the advertised figure is low but whether it is the figure billed. A membership charged outside the headline, as at Eden, a four-week supply labeled as a month, as at Piper, or a rate that exists only inside a prepaid term, as at Corsica Health, each move the real number by more than the gap between two sellers’ advertised prices.
Whether paying cash changes an outcome is a question with no direct trial evidence. Nobody has randomized patients to a cash-pay telehealth seller against an insured pathway and measured weight change, and the discontinuation data above comes from insured cohorts whose copays are mostly far below the cash figures on this site. What can be said is narrower and still useful: the sums are larger, and stopping is common at sums much smaller.